<DOC>
	<DOCNO>NCT02906202</DOCNO>
	<brief_summary>This single-arm , multi-site , single-dose , Phase 3 study approximately 15 subject ≥12 ≤50 year age transfusion-dependent β-thalassemia ( TDT ) , also know β-thalassemia major , β0 mutation allele hemoglobin β ( HBB ) gene . The study evaluate efficacy safety autologous hematopoietic stem cell transplantation ( HSCT ) use LentiGlobin BB305 Drug Product .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety LentiGlobin® BB305 Drug Product Subjects With Transfusion-Dependent β-Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Subjects 12 50 year age , inclusive , time consent assent ( applicable ) , able provide write consent assent . Diagnosis TDT history least 100 mL/kg/year pack red blood cell ( pRBCs ) ≥8 transfusion pRBCs per year prior 2 year . Clinically stable eligible undergo hematopoietic stem cell therapy ( HSCT ) . Treated follow least past 2 year specialize center maintain detailed medical record , include transfusion history . Presence mutation characterize β0 mutation allele HBB gene . Positive presence human immunodeficiency virus type 1 2 ( HIV1 HIV2 ) , hepatitis B virus ( HBV ) , hepatitis C ( HCV ) . A white blood cell ( WBC ) count &lt; 3×10^9/L , and/or platelet count &lt; 100×10^9/L related hypersplenism . Uncorrected bleed disorder . Any prior current malignancy . Prior HSCT . Advanced liver disease . A cardiac T2* &lt; 10 m magnetic resonance imaging ( MRI ) . Any evidence severe iron overload , Investigator 's opinion , warrant exclusion . Participation another clinical study investigational drug within 30 day Screening . Any condition would render subject ineligible HSCT , determine attend transplant physician investigator . Prior receipt gene therapy . Pregnancy breastfeed postpartum female absence adequate contraception fertile subject . A know available HLAmatched family donor .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>